Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for China Biotech Services Holdings's 5-Year Yield-on-Cost % or its related term are showing as below:
During the past 13 years, China Biotech Services Holdings's highest Yield on Cost was 3.85. The lowest was 1.39. And the median was 2.60.
HKSE:08037's 5-Year Yield-on-Cost % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 2.37 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
China Biotech Services Holdings (HKSE:08037) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
China Biotech Services Holdings 5-Year Yield-on-Cost % Related Terms
HKSE:08037 vs TMO, DHR, IDXX: 5-Year Yield-on-Cost % Comparison
For the Diagnostics & Research subindustry, China Biotech Services Holdings's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Biotech Services Holdings 5-Year Yield-on-Cost % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, China Biotech Services Holdings's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where China Biotech Services Holdings's 5-Year Yield-on-Cost % falls into.
China Biotech Services Holdings 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
China Biotech Services Holdings (HKSE:08037) has a 5-Year Yield-on-Cost % of 0.00 as of Aug. 17, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on China Biotech Services Holdings and its competitors. Over the past decade, China Biotech Services Holdings' 5-Year Yield-on-Cost % has ranged from 1.39 to 3.85. According to the industry distribution chart, China Biotech Services Holdings ranks #999999 out of 62 companies in the Medical Diagnostics & Research industry.
Is China Biotech Services Holdings' 5-Year Yield-on-Cost % too high?
China Biotech Services Holdings' current 5-Year Yield-on-Cost % is 0.00. Over the past 10 years, this metric has ranged from a low of 1.39 to a high of 3.85. Based on the distribution chart, China Biotech Services Holdings ranks #999999 out of 62 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, China Biotech Services Holdings has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does China Biotech Services Holdings' 5-Year Yield-on-Cost % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, China Biotech Services Holdings ranks #999999 out of 62 companies for 5-Year Yield-on-Cost %. This places China Biotech Services Holdings in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.37. Historically, China Biotech Services Holdings' own 5-Year Yield-on-Cost % has ranged from 1.39 to 3.85 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Diagnostics & Research company?
The median 5-Year Yield-on-Cost % among Medical Diagnostics & Research companies is 2.37, based on 62 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on China Biotech Services Holdings and its competitors. For the Medical Diagnostics & Research industry, the median 5-Year Yield-on-Cost % is 2.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Biotech Services Holdings's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Biotech Services Holdings stock overvalued right now?
Based on GuruFocus' analysis, China Biotech Services Holdings (HKSE:08037) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.26, compared to a current price of HK$0.63 — trading 140.4% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. China Biotech Services Holdings' overall GF Score™ is 31/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For China Biotech Services Holdings (HKSE:08037), the current 5-Year Yield-on-Cost % is 0.00 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Biotech Services Holdings (HKSE:08037) Overvalued in 2026?
Based on GuruFocus' analysis, China Biotech Services Holdings stock appears to be overvalued.
The current stock price of HK$0.63 is trading 140.4% above its estimated GF Value™ of HK$0.26.
GuruFocus considers China Biotech Services Holdings to be Significantly Overvalued.
Key valuation signals for HKSE:08037:
5-Year Yield-on-Cost %: 0.00
GF Value™: HK$0.26 vs. price of HK$0.63 (140.4% above fair value)
No single metric tells the full story. See the HKSE:08037 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Biotech Services Holdings Ltd is an investment holding company. It operates through five segments: Pharmaceutical Products, Medical and Health-Related Services, Immunotherapy, Insurance brokerage, BNCT, and Others. It derives prime revenue from the Medical & health-related services segment, which involves the provision of medical laboratory testing & health check services. The group has a business presence in Hong Kong & the PRC, of which key revenue is generated from Hong Kong. Immunotherapy-provision of tumor immune cell therapy & health management services. Pharmaceutical products-sale & distribution of health-related & pharmaceutical products. Insurance brokerage services. BNCT-provision of boron neutron capture therapy treatment services, & Others-provision of logistic services.
31GF Score
Get the complete analysis for HKSE:08037
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:08037 has been successfully added to your 
